AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02719002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spectral domain optical coherence tomography C-scan and multifocal electroretinogram
Study NCT04445090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912
Study NCT04445090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02097511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate pretreatment
Description: Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days
Study NCT02097511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpogrelate
Description: Sarpogrelate hydrochloride 100 mg three times a day
Study NCT02097511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Description: Sarpogrelate hydrochloride 100 mg three times a day
Study NCT02097511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol Tartrate 100 mg once a day
Study NCT04149704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP video decision aid
Description: 10 minute video decision aid describing the goals-of-care options
Study NCT04149704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care-
Description: Verbal description of the three types of care
Study NCT03744793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT03744793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT04470453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples will be collected for measuring PG-MTX blood concentration.
Study NCT04470453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CRQ
Description: Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
Study NCT02097511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol Tartrate 100 mg once a day
Study NCT03101384 — intervention group
Intervention type: OTHER
Intervention: Diagnostic error
Description: There is no intervention in our study. Patient will be managed with usual care. We will divide patients in the 2 groups according to the presence of diagnostic error.
Study NCT01649362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prefeeding oral stimulation program
Description: The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.~The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day.
Study NCT02335879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gonal-F
Study NCT04007510 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EPI-CAL data network
Description: This mobile, app-based platform was designed to: 1) enable outcomes data collection from clients and family members/support person who are receiving care at an early psychosis program, 2) summarize the data visually for clients and providers on a secure web-based dashboard, and 3) allow download of de-identified data for program or research analysis.
Study NCT04007510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Community DUP Assessment Tool
Description: A tool will be developed to enable measurement of the duration of untreated psychosis (DUP) for FEP individuals based on 1) data other assessments that are typically completed during the intake process (e.g. SIPS, SCID) or 2) specific questions, prompts, a rating scale, and anchor points to enable rating of the DUP. Participants would have their DUP rated on the new tool and also complete a second assessment of DUP by research evaluators using the Symptom Onset in Schizophrenia Inventory (SOS) to determine reliability and validity of the new tool.
Study NCT01763827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT01763827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day
Study NCT03127007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.
Study NCT03127007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU based radio-chemotherapy
Description: IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
Study NCT03127007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU based radio-chemotherapy
Description: IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
Study NCT04128683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amisulpride
Description: Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
Study NCT04128683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromocriptine
Description: Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
Study NCT01763827 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT01763827 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT01763827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Ezetimibe
Description: Administered orally once daily
Study NCT01763827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ezetimibe
Description: Administered orally once daily
Study NCT01127048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suppositories containing Ivy leaves dry extract
Description: Suppositories containing Ivy leaves dry extract
Study NCT01127048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suppositories containing no Ivy leaves dry extract
Study NCT01293747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol + Progesterone
Description: Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
Study NCT01293747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol + Progesterone
Description: Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
Study NCT01912794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Intervention
Description: 1. full sensory information, whose participants will practice balancing tasks without constraint sensory body;~2. sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;~3. control, whose participants will exercise activities involving cognitive and upper limbs.
Study NCT01420237 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restoration ADM X3 Device
Description: Restoration ADM X3 Device in total hip replacement.
Study NCT03026127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal Intervention for Suicide Prevention
Description: Cognitive Reappraisal Intervention for Suicide Prevention, or CRISP, is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
Study NCT03026127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors
Study NCT04332367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV
Study NCT04332367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV
Study NCT04332367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab IV
Study NCT04573946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo
Study NCT04573946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo
Study NCT04573946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT04573946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT04573946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Study NCT04573946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.~Other Names: cholecalciferol
Study NCT03994653 — intervention group
Intervention type: OTHER
Intervention: Risk Factor Questionnaire
Description: For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.
Study NCT03994653 — intervention group
Intervention type: OTHER
Intervention: Clinical Questionnaire
Description: For cases, the study recruiter at the trust will complete this form together with the participant. Controls will not complete this form.
Study NCT01731327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified-release (MR) formulation
Description: A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
Study NCT01731327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified-release (MR) formulation
Description: A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
Study NCT01726465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.
Study NCT01726465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°-110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
Study NCT03697941 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
Description: Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
Study NCT03697941 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical cut-down and arterial puncture under direct vision
Description: Surgical cut-down and arterial puncture under direct vision.
Study NCT00758498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: 50 mg/day orally, once daily in the morning for 3 days
Study NCT00758498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: 150 mg/day orally, once daily in the morning for 3 days
Study NCT00758498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets, once daily in the morning for 3 days
Study NCT01563198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfort Talk®
Description: Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
Study NCT01310127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
Study NCT01310127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac
Description: nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
Study NCT00610272 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
Study NCT00610272 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
Study NCT00610272 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
Study NCT00610272 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
Study NCT02366299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Treatment of delirium by dexmedetomidine i.v. infusion
Study NCT02366299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Treatment of delirium by Propofol i.v. infusion
Study NCT03162042 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor removal
Description: Surgery
Study NCT04447469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mavrilimumab
Description: anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])
Study NCT03017391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity
Study NCT03017391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron
Description: granisetron patch 3.1mg/24 hours, use until toxicity
Study NCT04447469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT03017391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 8 mg, last step in both algorithms
Study NCT03017391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron 2Mg Tablet
Description: granisetron 2 mg loading dose
Study NCT02052297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GSK2634673F
Description: GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
Study NCT01420250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Administered weekly on the same day of radiation according to the following infusion levels:~Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;
Study NCT01420250 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy
Study NCT01420250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Androgen Therapy: Bicalutamide
Description: * Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)~* Will continue once daily until the final day of IMRT
Study NCT01420250 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Description: * First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)~* Will continue for 24 months after IMRT~* Total administered duration and agent used must be documented on the case report form
Study NCT01738919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment with splinting for 6 weeks.
Description: Aluminum Karstam splints are used.
Study NCT01738919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment with extension block technique
Description: Surgery with extension block technique. 6 weeks.
Study NCT00652145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine
Description: Increase dose by 2.4gm per day over baseline dose
Study NCT01639144 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP and PPP
Description: Autogenous PRP and PPP
Study NCT02937740 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NATESTO Testosterone Nasal Gel
Description: Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 \[Day 90\] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone.
Study NCT04566718 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: metformin cessation
Study NCT02608996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
Study NCT02608996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For comparison to elucidate the true effect of nesiritide